Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Interest Expenses (2019 - 2025)

Addex Therapeutics' Interest Expenses history spans 7 years, with the latest figure at $37138.5 for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 116.74% to $37138.5 in Q4 2025 year-over-year; TTM through Dec 2025 was $21857.1, a 1175.41% increase, with the full-year FY2025 number at $18751.7, up 920.94% from a year prior.
  • Interest Expenses came in at $37138.5 for Q4 2025, up from -$1021.3 in the prior quarter.
  • The five-year high for Interest Expenses was $159568.0 in Q4 2023, with the low at -$154106.4 in Q2 2023.
  • Historically, Interest Expenses has averaged $4782.3 across 5 years, with a median of -$988.37 in 2024.
  • Peak annual rise in Interest Expenses hit 836.82% in 2025, while the deepest fall reached 2942.75% in 2025.
  • Year by year, Interest Expenses stood at $126539.7 in 2021, then rose by 12.24% to $142024.2 in 2022, then grew by 12.35% to $159568.0 in 2023, then tumbled by 89.26% to $17135.4 in 2024, then soared by 116.74% to $37138.5 in 2025.
  • Business Quant data shows Interest Expenses for ADXN at $37138.5 in Q4 2025, -$1021.3 in Q3 2025, and $7039.6 in Q2 2025.